© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 6, 430-437,
March 20, 2002
© 2002 Oxford University Press
ARTICLE |
Quality of Life Following Localized Prostate Cancer Treated Initially with Androgen Deprivation Therapy or No Therapy
Affiliations of authors: Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD; Medical Service, Department of Veterans Affairs Medical Center, Albuquerque, NM; Division of Urology, Department of Surgery, University of Utah, Salt Lake City; Division of Urology, University of Connecticut Health Center, Farmington; Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles; Fred Hutchinson Cancer Research Center, Seattle, WA.
Correspondence to: Arnold L. Potosky, Ph.D., Applied Research Program, NCI, EPN Rm. 4005, 6130 Executive Blvd., MSC 7344, Bethesda, MD 20892–7344 (e-mail: potosky{at}nih.gov).
Background: Many men diagnosed with clinically localized prostate cancer are initially treated conservatively, receiving neither surgery nor radiotherapy for the first year. Treatment patterns and quality-of-life outcomes have not been previously reported for a population-based sample of such men. Methods: A population-based random sample of men (n = 661) from six geographic regions who had been newly diagnosed with clinically localized prostate cancer from 1994 through 1995 were followed for up to 1 year. Eligible subjects received neither surgery nor radiotherapy within 1 year of initial diagnosis. We assessed disease-specific and generic quality-of-life outcomes in men receiving androgen deprivation therapy (ADT) compared with men receiving no therapy. All statistical tests were two-sided. Results: Two hundred and forty-five study patients received ADT and the remaining 416 patients received no therapy. Approximately two thirds of the patients (n = 159) receiving ADT had either baseline Gleason scores greater than six or serum prostate-specific antigen values above 20 ng/mL. Among men who were sexually potent before diagnosis (ADT = 88 patients; no therapy = 223 patients), 80% of those on ADT reported being impotent after 1 year compared with 30% of those receiving no treatment (P < .001). Patients receiving ADT reported more physical discomfort 1 year after diagnosis than did men who had received no therapy. However, patients receiving ADT, compared with those receiving no therapy, were more likely to be satisfied with their treatment decision (56% pleased versus 45.3%; P = .001). Patients on ADT also experienced a statistically significant decline in vitality, but not in physical function, after adjustment for the confounding factors (P = .05). Conclusion: ADT is a commonly used primary therapy for clinically localized prostate cancer. Therefore, men considering ADT as an initial treatment should be aware that sexual function and some aspects of physical well-being are likely to be affected in the first year following this treatment.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. L. Lu-Yao, P. C. Albertsen, D. F. Moore, W. Shih, Y. Lin, R. S. DiPaola, and S.-L. Yao Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer JAMA, July 9, 2008; 300(2): 173 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Saigal Moving Beyond Guidelines to Improve the Quality of Care for Men With Prostate Cancer J. Clin. Oncol., December 1, 2007; 25(34): 5348 - 5349. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Stephenson, P. T. Scardino, M. W. Kattan, T. M. Pisansky, K. M. Slawin, E. A. Klein, M. S. Anscher, J. M. Michalski, H. M. Sandler, D. W. Lin, et al. Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy J. Clin. Oncol., May 20, 2007; 25(15): 2035 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Keating, A. J. O'Malley, and M. R. Smith Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer J. Clin. Oncol., September 20, 2006; 24(27): 4448 - 4456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W S A Smellie, J Forth, S Sundar, E Kalu, C A M McNulty, E Sherriff, I D Watson, C Croucher, T M Reynolds, and P J Carey Best practice in primary care pathology: review 4 J. Clin. Pathol., September 1, 2006; 59(9): 893 - 902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Salminen, R. I. Portin, A. Koskinen, H. Helenius, and M. Nurmi Associations between Serum Testosterone Fall and Cognitive Function in Prostate Cancer Patients Clin. Cancer Res., November 15, 2004; 10(22): 7575 - 7582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Clark, T. S. Inui, R. A. Silliman, B. G. Bokhour, S. H. Krasnow, R. A. Robinson, M. Spaulding, and J. A. Talcott Patients' Perceptions of Quality of Life After Treatment for Early Prostate Cancer J. Clin. Oncol., October 15, 2003; 21(20): 3777 - 3784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Hoffman An Argument Against Routine Prostate Cancer Screening Arch Intern Med, March 24, 2003; 163(6): 663 - 665. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Harris and K. N. Lohr Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, December 3, 2002; 137(11): 917 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Talcott Androgen Deprivation as Primary Treatment for Early Prostate Cancer: Should We "Just Do Something"? J Natl Cancer Inst, March 20, 2002; 94(6): 407 - 409. [Full Text] [PDF]
|
|